267 related articles for article (PubMed ID: 34646778)
1. Application of Organoid Models in Prostate Cancer Research.
Zhou L; Zhang C; Zhang Y; Shi C
Front Oncol; 2021; 11():736431. PubMed ID: 34646778
[TBL] [Abstract][Full Text] [Related]
2. A synopsis of prostate organoid methodologies, applications, and limitations.
Gleave AM; Ci X; Lin D; Wang Y
Prostate; 2020 May; 80(6):518-526. PubMed ID: 32084293
[TBL] [Abstract][Full Text] [Related]
3. Organoids: An Emerging Precision Medicine Model for Prostate Cancer Research.
Waseem M; Wang BD
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256166
[TBL] [Abstract][Full Text] [Related]
4. [Progress in prostate cancer study: 3D cell culture enables the ex vivo reproduction of tumor characteristics].
Tostivint V; Racaud-Sultan C; Roumiguié M; Soulié M; Gamé X; Beauval JB
Presse Med; 2017 Oct; 46(10):954-965. PubMed ID: 28967525
[TBL] [Abstract][Full Text] [Related]
5. Application of Prostate Cancer Models for Preclinical Study: Advantages and Limitations of Cell Lines, Patient-Derived Xenografts, and Three-Dimensional Culture of Patient-Derived Cells.
Namekawa T; Ikeda K; Horie-Inoue K; Inoue S
Cells; 2019 Jan; 8(1):. PubMed ID: 30669516
[TBL] [Abstract][Full Text] [Related]
6. Prostate cancer patient-derived organoids: detailed outcome from a prospective cohort of 81 clinical specimens.
Servant R; Garioni M; Vlajnic T; Blind M; Pueschel H; Müller DC; Zellweger T; Templeton AJ; Garofoli A; Maletti S; Piscuoglio S; Rubin MA; Seifert H; Rentsch CA; Bubendorf L; Le Magnen C
J Pathol; 2021 Aug; 254(5):543-555. PubMed ID: 33934365
[TBL] [Abstract][Full Text] [Related]
7. Engineering prostate cancer in vitro: what does it take?
Buskin A; Scott E; Nelson R; Gaughan L; Robson CN; Heer R; Hepburn AC
Oncogene; 2023 Aug; 42(32):2417-2427. PubMed ID: 37438470
[TBL] [Abstract][Full Text] [Related]
8. Use of conditional reprogramming cell, patient derived xenograft and organoid for drug screening for individualized prostate cancer therapy: Current and future perspectives (Review).
Cao J; Chan WC; Chow MSS
Int J Oncol; 2022 May; 60(5):. PubMed ID: 35322860
[TBL] [Abstract][Full Text] [Related]
9. Standardization of organoid culture in cancer research.
Zhou C; Wu Y; Wang Z; Liu Y; Yu J; Wang W; Chen S; Wu W; Wang J; Qian G; He A
Cancer Med; 2023 Jul; 12(13):14375-14386. PubMed ID: 37081739
[TBL] [Abstract][Full Text] [Related]
10. Development of patient-derived xenograft models of prostate cancer for maintaining tumor heterogeneity.
Shi C; Chen X; Tan D
Transl Androl Urol; 2019 Oct; 8(5):519-528. PubMed ID: 31807428
[TBL] [Abstract][Full Text] [Related]
11. Advantages and limitations of 3D organoids and ex vivo tumor tissue culture in personalized medicine for prostate cancer.
Mickova A; Morong M; Levková M; Kurfúrstová D; Kharaishvili G; Überall I; Student V; Student V; Drapela S; Soucek K; Bouchal J
Klin Onkol; 2022; 35(6):473-481. PubMed ID: 36513514
[TBL] [Abstract][Full Text] [Related]
12. Establishment and characterization of prostate organoids from treatment-naïve patients with prostate cancer.
Cheaito K; Bahmad HF; Hadadeh O; Msheik H; Monzer A; Ballout F; Dagher C; Telvizian T; Saheb N; Tawil A; El-Sabban M; El-Hajj A; Mukherji D; Al-Sayegh M; Abou-Kheir W
Oncol Lett; 2022 Jan; 23(1):6. PubMed ID: 34820005
[TBL] [Abstract][Full Text] [Related]
13. Prostate Cancer Organoids for Tumor Modeling and Drug Screening.
Yehya A; Ghamlouche F; Hachem S; Abou-Kheir W
Methods Mol Biol; 2024; 2777():135-144. PubMed ID: 38478341
[TBL] [Abstract][Full Text] [Related]
14. Viability Analysis and High-Content Live-Cell Imaging for Drug Testing in Prostate Cancer Xenograft-Derived Organoids.
Van Hemelryk A; Erkens-Schulze S; Lim L; de Ridder CMA; Stuurman DC; Jenster GW; van Royen ME; van Weerden WM
Cells; 2023 May; 12(10):. PubMed ID: 37408211
[TBL] [Abstract][Full Text] [Related]
15. Establishment of patient-derived three-dimensional organoid culture in renal cell carcinoma.
Na JC; Kim JH; Kim SY; Gu YR; Jun DY; Lee HH; Yoon YE; Choi KH; Hong SJ; Han WK
Investig Clin Urol; 2020 Mar; 61(2):216-223. PubMed ID: 32158973
[TBL] [Abstract][Full Text] [Related]
16. Modeling Prostate Cancer Treatment Responses in the Organoid Era: 3D Environment Impacts Drug Testing.
Van Hemelryk A; Mout L; Erkens-Schulze S; French PJ; van Weerden WM; van Royen ME
Biomolecules; 2021 Oct; 11(11):. PubMed ID: 34827570
[TBL] [Abstract][Full Text] [Related]
17. [Exploration of organoid in breast cancer related research].
Zheng X; Li J; Sheng J; Zhuo Q; Du Q; Xu Y
Sheng Wu Gong Cheng Xue Bao; 2021 Feb; 37(2):395-403. PubMed ID: 33645143
[TBL] [Abstract][Full Text] [Related]
18. Organoid technology and applications in cancer research.
Xu H; Lyu X; Yi M; Zhao W; Song Y; Wu K
J Hematol Oncol; 2018 Sep; 11(1):116. PubMed ID: 30219074
[TBL] [Abstract][Full Text] [Related]
19. Current status and clinical application of patient-derived tumor organoid model in kidney and prostate cancers.
Seo E; Kang M
BMB Rep; 2023 Jan; 56(1):24-31. PubMed ID: 36476272
[TBL] [Abstract][Full Text] [Related]
20. Drug screening model meets cancer organoid technology.
Liu C; Qin T; Huang Y; Li Y; Chen G; Sun C
Transl Oncol; 2020 Nov; 13(11):100840. PubMed ID: 32822897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
